{"createdAt":"8/2/2020, 2:34:05 PM","timestamp":1596393245132,"Company ID number":"616","DMX_ISSUER_NAME":"China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.","DMX_ISSUER_ID":"IID000000002182659","Country of Classification":"CHINA","name":"China Resources Sanjiu Medical & Pharmaceutical Co Ltd ","code":"000999","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"华润三九医药股份有限公司_王春城","group":"board","name":"王春城","title":"董事长,董事","isMale":true,"age":"58","degree":"本科","salary":"0.00","stockAmount":"-","description":"王春城先生,1962年12月出生,吉林财贸学院经济学学士学位。曾任国家外经贸部(现为商务部)人事司副处长,中国华润有限公司人事部副总经理、总经理,中国华润有限公司助理总经理,华润(集团)有限公司常务董事会办公室副总经理、总经理,德信行有限公司董事长、总经理,华润纺织(集团)有限公司董事长,华润三九医药股份有限公司董事长。现任华润(集团)有限公司助理总经理,华润医药集团有限公司执行董事、首席执行官,华润医药控股有限公司党委书记、董事长,北京医药集团有限责任公司、华润医药商业集团有限公司、东阿阿胶股份有限公司、华润双鹤药业股份有限公司董事长。于2019年3月21日获委任为华润医药集团有限公司董事会主席。于2019年10月22日调任为华润医药集团有限公司非执行董事。","lastUpdated":"2018-09-20"},{"id":"华润三九医药股份有限公司_邱华伟","group":"board","name":"邱华伟","title":"董事","isMale":true,"age":"53","degree":"本科","salary":"427.1万","stockAmount":"-","description":"邱华伟先生:男,1967年5月出生,高级工程师。1989年7月毕业于复旦大学生物工程系遗传工程专业,本科学历。曾任深圳南方药厂经贸部业务员、业务主管、片区经理,深圳市三九医药贸易有限公司副总经理,深圳九升生物制品厂厂长,深圳三九药业有限公司投资部部长,宁波立华制药有限公司总经理,宁波药材股份有限公司总经理,深圳九升生物制品有限公司总经理,三九企业集团医药事业部副部长,华润三九高级副总裁。现任华润三九董事、总裁。邱华伟先生于2019年5月29日获委任为华润医药集团有限公司执行董事。","lastUpdated":"2018-04-28"},{"id":"华润三九医药股份有限公司_周辉","group":"board","name":"周辉","title":"董事","isMale":false,"age":"49","degree":"硕士","salary":"255.1万","stockAmount":"-","description":"周辉女士:女,出生于1971年2月,经济学硕士,会计师,注册会计师。曾任深圳市三九医药贸易有限公司投资管理部部长助理,深圳市三九医药连锁股份有限公司业务发展与投资管理中心负责人。周辉女士已取得深圳证券交易所颁发的“董事会秘书资格证书”。现任华润三九董事、副总裁、董事会秘书。","lastUpdated":"2018-04-28"},{"id":"华润三九医药股份有限公司_刘文涛","group":"board","name":"刘文涛","title":"董事","isMale":true,"age":"48","degree":"硕士","salary":"0.00","stockAmount":"-","description":"刘文涛先生:男,出生于1972年5月,北京大学经济学硕士学位。曾任合宜咨询公司顾问,高级顾问,韬睿咨询公司资深顾问,咨询总监,美世咨询公司华南区总经理,华润集团人力资源部副总监,华润医药集团有限公司副总经理兼首席人力资源官。现任华润集团人力资源部高级副总监,华润三九董事。","lastUpdated":"2018-04-24"},{"id":"华润三九医药股份有限公司_郭巍","group":"board","name":"郭巍","title":"董事","isMale":false,"age":"44","degree":"硕士","salary":"0.00","stockAmount":"-","description":"郭巍女士,1976年3月出生,对外经济贸易大学经济学学士学位,北京大学研究生院法学硕士学位。曾任华润轻纺投资发展有限公司内审部高级经理,华润创业有限公司内审部经理,华润(集团)有限公司审计监察部经理、高级审计师,财务部高级经理、助理总监。现任华润(集团)有限公司财务部副总监,华润三九医药股份有限公司、华润双鹤药业股份有限公司董事。郭巍女士于2019年5月29日获委任为华润医药集团有限公司非执行董事。","lastUpdated":"2018-04-24"},{"id":"华润三九医药股份有限公司_韩跃伟","group":"board","name":"韩跃伟","title":"董事","isMale":true,"age":"52","degree":"硕士","salary":"0.00","stockAmount":"-","description":"韩跃伟先生:男,1968年3月出生,持有清华大学土木工程系建筑管理学士学位和清华大学建筑经济与管理硕士学位,曾任深圳市建筑工务署市政处处长、华润集团深圳区域工委书记、华润置地有限公司副总裁、华润医疗控股有限公司行政总裁、华润健康集团有限公司党委副书记、总经理等职务。现任华润医药控股有限公司党委书记、华润医药集团有限公司执行董事、首席执行官。","lastUpdated":"2019-12-14"},{"id":"华润三九医药股份有限公司_邓荣辉","group":"board","name":"邓荣辉","title":"董事","isMale":true,"age":"49","degree":"硕士","salary":"0.00","stockAmount":"-","description":"邓荣辉先生:男,1971年6月出生,清华大学工学学士学位及中国香港大学工商管理学硕士学位,工程师资格。曾任华润营造(控股)有限公司董事、董事助理总经理,华润物业有限公司副总经理。现任华润(集团)有限公司战略管理部助理总监。","lastUpdated":"2019-12-14"},{"id":"华润三九医药股份有限公司_姚兴田","group":"board","name":"姚兴田","title":"独立董事","isMale":true,"age":"64","degree":"本科","salary":"15.00万","stockAmount":"-","description":"姚兴田先生:男,出生于1956年10月,毕业于中国药科大学药学系,高级工程师。曾任扬州制药厂技术员、车间副主任、主任、副厂长;江苏联环药业股份有限公司董事长;江苏联环药业集团有限公司副董事长、总经理、董事长;江苏金茂化工医药集团公司副董事长;南京大学第三届校董事会董事。曾获得“扬州市劳动模范”、“江苏省医药系统劳动模范”等荣誉称号。","lastUpdated":"2018-04-24"},{"id":"华润三九医药股份有限公司_许芳","group":"board","name":"许芳","title":"独立董事","isMale":false,"age":"57","degree":"硕士","salary":"15.00万","stockAmount":"-","description":"许芳女士:女,出生于1963年11月,纽约理工大学工商管理硕士学位。曾任TCL集团股份有限公司人力资源总监、TCL多媒体科技控股公司CHO(首席人力资源官)。现任TCL集团股份有限公司副总裁、TCL大学执行校长;兼任新华都商学院/北大汇丰商学院人力资源企业教授/导师。中国CHO100联席理事长。","lastUpdated":"2018-04-24"},{"id":"华润三九医药股份有限公司_屠鹏飞","group":"board","name":"屠鹏飞","title":"独立董事","isMale":true,"age":"57","degree":"博士","salary":"15.00万","stockAmount":"-","description":"屠鹏飞,中国国籍,无境外居留权,男,1963年4月生,博士、教授。北京大学药学院教授、博士生导师,北京大学中医药现代研究中心主任,兼任北京中医药大学中药现代研究中心主任。第十一届国家药典委员会执委、中药材和饮片第二专业委员会主任委员。《中国药学》英文版、《中药新药与临床药理》、《中国现代中药》杂志副主编,《JournalofChromatographyB》、《中国药学杂志》等10多家杂志编委。国家杰出青年基金获得者。先后承担了国家和省部级项目70余项。成功研制二类新药2项,获得新药证书4个,在研一类、五类新药10多项。现任北京中关村科技发展(控股)股份有限公司、华润三九医药股份有限公司、湖北济川药业股份有限公司独立董事。","lastUpdated":"2018-04-24"},{"id":"华润三九医药股份有限公司_刘俊勇","group":"board","name":"刘俊勇","title":"独立董事","isMale":true,"age":"50","degree":"博士","salary":"15.00万","stockAmount":"-","description":"刘俊勇先生:男,出生于1970年10月,河南财经学院工业经济系毕业获经济学学士学位、中国人民大学商学院会计系毕业获管理学(会计学)硕士学位和管理学(会计学)博士学位,教授、博士生导师。现任中央财经大学会计学院党委书记、教授、博士生导师,中央财经大学中国管理会计研究与发展中心执行主任,中国建材检验认证集团股份有限公司、中国机械国际合作股份有限公司独立董事。中国卫生经济学会卫生财会分会副会长。","lastUpdated":"2018-04-24"},{"id":"华润三九医药股份有限公司_陶然","group":"supervisoryCommittee","name":"陶然","title":"监事会主席","isMale":true,"age":"54","degree":"硕士","salary":"0.00","stockAmount":"-","description":"陶然先生,于二零一七年六月获任华润医药集团有限公司助理总裁。陶先生曾任中国华润总公司(现为中国华润有限公司)进口一部副科长,华润纺织集团有限公司投资部高级经理、战略部总经理、公司副总经理,华润医药战略发展部高级总监、战略发展部总经理。陶先生持有位于中国上海市的上海交通大学授予的工学学士学位及位于中国北京市的北京航空航天大学经济管理学院授予的经济学硕士学位。","lastUpdated":"2019-05-28"},{"id":"华润三九医药股份有限公司_唐娜","group":"supervisoryCommittee","name":"唐娜","title":"监事","isMale":false,"age":"44","degree":"硕士","salary":"0.00","stockAmount":"-","description":"唐娜:女,1976年12月出生,持有中国政法大学法学学士学位,曾于中国人民大学城市经济学专业研究生班学习。曾任北京市共和律师事务所合伙人、华润医药商业法律事务总监。现任华润医药集团有限公司总法律顾问。","lastUpdated":"2019-06-19"},{"id":"华润三九医药股份有限公司_翁菁雯","group":"supervisoryCommittee","name":"翁菁雯","title":"监事","isMale":false,"age":"44","degree":"硕士","salary":"0.00","stockAmount":"-","description":"翁菁雯女士:女,1976年1月出生,持有浙江大学经济学学士及中国香港科技大学工商管理硕士学位,曾任普华永道中天会计师事务所审计和商业咨询部高级审计师、华润燃气(集团)有限公司内审部总经理、审计总监、战略总监、华润(集团)有限公司战略管理部副总监等职务。现任华润医药集团有限公司党委委员、副总裁、首席财务官。","lastUpdated":"2019-12-14"},{"id":"华润三九医药股份有限公司_张继红","group":"supervisoryCommittee","name":"张继红","title":"职工监事","isMale":true,"age":"49","degree":"硕士","salary":"64.15万","stockAmount":"-","description":"张继红先生:男,出生于1971年3月,武汉中南财经政法大学统计学专业本科毕业、北京大学经济学院研究生在职学习,经济师、非执业注册会计师。曾任深圳三九医药贸易有限公司财务部财务主管、审计监察部部长。现任华润三九医药股份有限公司财务管理中心风险管理部(副)总监。","lastUpdated":"2018-04-24"},{"id":"华润三九医药股份有限公司_陈丹","group":"supervisoryCommittee","name":"陈丹","title":"职工监事","isMale":false,"age":"50","degree":"大专","salary":"49.79万","stockAmount":"-","description":"陈丹女士:女,出生于1970年11月,1990年7月毕业于广东省医药学校财会专业,1995年9月至1997年12月就读于中央党校经济管理专业,大学专科学历。曾任南方制药厂财务部出纳、会计,九升生物制品厂会计、三九集团财务结算中心主管会计、三九医药股份有限公司主管会计、华润三九医药股份有限公司资金管理经理等。现任华润三九医药股份有限公司财务管理中心融资管理高级主任。","lastUpdated":"2018-04-24"},{"id":"华润三九医药股份有限公司_邱华伟","group":"manager","name":"邱华伟","title":"总裁","isMale":true,"age":"53","degree":"本科","salary":"427.1万","stockAmount":"-","description":"邱华伟先生:男,1967年5月出生,高级工程师。1989年7月毕业于复旦大学生物工程系遗传工程专业,本科学历。曾任深圳南方药厂经贸部业务员、业务主管、片区经理,深圳市三九医药贸易有限公司副总经理,深圳九升生物制品厂厂长,深圳三九药业有限公司投资部部长,宁波立华制药有限公司总经理,宁波药材股份有限公司总经理,深圳九升生物制品有限公司总经理,三九企业集团医药事业部副部长,华润三九高级副总裁。现任华润三九董事、总裁。邱华伟先生于2019年5月29日获委任为华润医药集团有限公司执行董事。","lastUpdated":"2018-04-28"},{"id":"华润三九医药股份有限公司_周辉","group":"manager","name":"周辉","title":"董事会秘书,副总裁","isMale":false,"age":"49","degree":"硕士","salary":"255.1万","stockAmount":"-","description":"周辉女士:女,出生于1971年2月,经济学硕士,会计师,注册会计师。曾任深圳市三九医药贸易有限公司投资管理部部长助理,深圳市三九医药连锁股份有限公司业务发展与投资管理中心负责人。周辉女士已取得深圳证券交易所颁发的“董事会秘书资格证书”。现任华润三九董事、副总裁、董事会秘书。","lastUpdated":"2018-04-28"},{"id":"华润三九医药股份有限公司_杨战鏖","group":"manager","name":"杨战鏖","title":"副总裁","isMale":true,"age":"59","degree":"本科","salary":"282.2万","stockAmount":"-","description":"杨战鏖先生:男,1961年5月出生,大学本科学历,高级工程师。曾任华润三九医药股份有限公司副总经理,总工程师,助理总裁。现任华润三九副总裁、抗感染事业部总经理。","lastUpdated":"2018-04-28"},{"id":"华润三九医药股份有限公司_麦毅","group":"manager","name":"麦毅","title":"副总裁","isMale":true,"age":"54","degree":"本科","salary":"280.6万","stockAmount":"1950","description":"麦毅先生:男,1966年7月出生,大学本科学历,主管药师。曾任深圳三九药业有限公司董事、副总经理、研究开发部部长,华润三九医药股份有限公司供应部部长,广东华润顺峰药业有限公司总经理,华润三九总监。现任华润三九副总裁、生产运营中心总经理。","lastUpdated":"2018-04-28"},{"id":"华润三九医药股份有限公司_谈英","group":"manager","name":"谈英","title":"副总裁","isMale":true,"age":"58","degree":"硕士","salary":"295.4万","stockAmount":"-","description":"谈英先生:男,1962年6月出生,研究生学历。曾任南方药厂技术开发部副部长、部长、党务部部长,深圳市三九医药贸易有限公司副总经理,山西三九同达药业公司常务副总经理、总经理。现任华润三九副总裁、研发中心总经理。","lastUpdated":"2018-04-28"},{"id":"华润三九医药股份有限公司_王进元","group":"manager","name":"王进元","title":"副总裁","isMale":true,"age":"57","degree":"硕士","salary":"283.0万","stockAmount":"-","description":"王进元先生:男,1963年12月出生,研究生学历。曾任淮北制药厂副厂长,金蟾生化股份公司副总经理、总经理、董事长,华润三九助理总裁。现任华润三九副总裁、中药配方颗粒事业部总经理。","lastUpdated":"2018-04-28"},{"id":"华润三九医药股份有限公司_梁征","group":"manager","name":"梁征","title":"财务总监,助理总裁","isMale":true,"age":"42","degree":"硕士","salary":"145.6万","stockAmount":"-","description":"梁征先生:男,1978年6月出生,1999年毕业于中央财经大学货币银行学专业,本科学历,获学士学位;2002年毕业于中国人民大学金融学专业,研究生学历,获硕士学位。曾任华润(集团)有限公司财务部高级经理,泰国长春置地有限公司财务董事,珠海华润银行股份有限公司运营管理部总经理、风险管理部总经理,华润租赁有限公司副总经理兼首席风险官,华润金融控股有限公司财务部总经理,现任华润三九医药股份有限公司财务管理中心负责人。","lastUpdated":"2019-10-30"},{"id":"华润三九医药股份有限公司_郭霆","group":"manager","name":"郭霆","title":"助理总裁","isMale":true,"age":"47","degree":"硕士","salary":"216.4万","stockAmount":"-","description":"郭霆先生:男,1973年3月出生,1995年毕业于南京财经大学会计学专业,会计学学士,2008年毕业于中欧国际工商管理学院工商管理专业,工商管理硕士;曾任北京双鹤药业股份有限公司财务总监、北京双鹤药业股份有限公司副总裁、华润北贸副总经理、华润北贸总经理、华润三九营销中心副总经理,现任华润三九医药股份有限公司营销中心副总经理(中心总经理级)。","lastUpdated":"2018-10-30"},{"id":"华润三九医药股份有限公司_王雁飞","group":"manager","name":"王雁飞","title":"助理总裁","isMale":true,"age":"48","degree":"硕士","salary":"236.4万","stockAmount":"-","description":"王雁飞先生:男,1972年10月出生,1995年毕业于中国人民大学商品学专业,本科学历,2003年毕业于美国德克萨斯大学阿灵顿分校工商管理专业,研究生学历;曾任华润三九医贸销售总监、华润三九医贸营销总监、华润三九医贸副总经理、华润三九营销中心副总经理,现任华润三九医药股份有限公司营销中心总经理兼金复康董事长。","lastUpdated":"2018-10-30"}],"companyName":"华润三九医药股份有限公司","province":"广东省","englishName":"China Resources Sanju Mdcl & Phrm Co Ltd","industry":"医药生物 — 中药Ⅱ","website":"www.999.com.cn","mainBusiness":"医药产品的研发、生产、销售及相关健康服务。","productsName":["999感冒灵","999皮炎平","参附注射液","注射用头孢","免煎中药","三九胃泰颗粒","正天丸"],"actualController":"国务院国有资产监督管理委员会","actualControllerSharePercentage":"33.73%","registeredCapital":"9.79亿元","employeeAmount":"14914","phone":"86-0755-83360999-393042;86-0398-612;86-0755-83360999-393692","location":"广东省深圳市宝安区龙华新区观澜高新园区观清路1号","chineseDescription":"华润三九医药股份有限公司主要从事医药产品的研发、生产、销售及相关健康服务。主要产品包括999感冒灵、999皮炎平、参附注射液、注射用头孢、免煎中药、三九胃泰颗粒、正天丸等。公司产品“参附注射液”,“红花注射液”、“参麦注射液”,“新泰林”,“血塞通软胶囊(理洫王)”为研究对象的科研项目先后获得国家科学技术进步奖二等奖。公司2018年度位列非处方药企业综合排名第一名。同时公司连续多年上榜WPP集团发布的最有价值中国品牌榜榜单，在《2019年最有价值中国品牌100强》排行榜中，公司位列榜单第83位。","foundedDate":"1999-03-02","goPublicDate":"2000-03-09","companyHistory":"","shareholders":[{"organizationId":"T000052192","holderName":"华润医药控股有限公司","totalShare":"6.23亿","sharePercentage":"63.60%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"1.03亿","sharePercentage":"10.48%"},{"organizationId":"","holderName":"全国社保基金一零三组合","totalShare":"3438.06万","sharePercentage":"3.51%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"1579.34万","sharePercentage":"1.61%"},{"organizationId":"","holderName":"安本标准投资管理(亚洲)有限公司-安本标准-中国A股股票基金","totalShare":"1523.87万","sharePercentage":"1.56%"},{"organizationId":"","holderName":"摩根士丹利投资管理公司-摩根士丹利中国A股基金","totalShare":"1207.56万","sharePercentage":"1.23%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1114.49万","sharePercentage":"1.14%"},{"organizationId":"","holderName":"天达资产管理有限公司-天达环球策略基金-全中国股票基金(交易所)","totalShare":"889.67万","sharePercentage":"0.91%"},{"organizationId":"T000127236","holderName":"涿州京南永乐高尔夫俱乐部有限公司","totalShare":"735.00万","sharePercentage":"0.75%"},{"organizationId":"00055242","holderName":"深圳市百业源投资有限公司","totalShare":"661.98万","sharePercentage":"0.68%"}],"englishDescription":"China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Company's pharmaceutical products include over the counter (OTC) drugs and prescription drugs. The Company's drugs are used for the treatment in cold, gastroenterology, dermatology, pediatrics, cardiovascular and cerebrovascular diseases, anti-tumor, anti-infection, digestive system, orthopedics and other areas. The Company is also involved in packaging and printing and international trading businesses. The Company distributes its products in domestic market and to overseas markets. ","englishIndustry":"Major Drugs","Price to earnings (ttm)":"20.05","Price to sales (ttm)":"2.07","Price to book (mrq)":"2.26","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"2.90","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"11.51","Return on equity (ttm)":"7.93","Income statement":{"Revenue":"14,701.92","Total revenue":"14,701.92","Cost of revenue, total":"4,830.07","Gross profit":"9,871.85","Selling/general/admin. expenses, total":"7,624.44","Research & development":"411.41","Depreciation/amortization":"94.74","Interest exp.(inc.),net-operating, total":"(14.78)","Unusual expense (income)":"(593.27)","Other operating expenses, total":"(179.22)","Total operating expense":"12,173.38","Operating income":"2,528.54","Other, net":"40.09","Net income before taxes":"2,568.63","Provision for income taxes":"429.55","Net income after taxes":"2,139.08","Minority interest":"(26.59)","Net income before extra. items":"2,112.49","Net income":"2,112.49","Income available to com excl extraord":"2,112.49","Income available to com incl extraord":"2,112.49","Diluted net income":"2,112.49","Diluted weighted average shares":"978.90","Diluted eps excluding extraord items":"2.16","Dps - common stock primary issue":"0.43","Diluted normalized eps":"1.65","Gain (loss) on sale of assets":"1.82"},"Balance sheet":{"Cash":"0.02","Cash & equivalents":"3,042.05","Cash and short term investments":"3,042.08","Accounts receivable - trade, net":"2,750.96","Total receivables, net":"5,604.36","Total inventory":"1,432.44","Prepaid expenses":"199.80","Other current assets, total":"14.13","Total current assets":"10,292.80","Property/plant/equipment, total - gross":"6,414.13","Accumulated depreciation, total":"(2,654.62)","Property/plant/equipment, total - net":"3,759.52","Goodwill, net":"3,353.68","Intangibles, net":"2,097.39","Long term investments":"55.37","Other long term assets, total":"544.76","Total assets":"20,103.53","Accounts payable":"708.53","Accrued expenses":"981.27","Notes payable/short term debt":"348.79","Current port. of  lt debt/capital leases":"0.00","Other current liabilities, total":"4,654.61","Total current liabilities":"6,693.19","Long term debt":"0.00","Total long term debt":"0.00","Total debt":"348.79","Deferred income tax":"140.59","Minority interest":"318.03","Other liabilities, total":"387.87","Total liabilities":"7,539.68","Common stock, total":"978.90","Additional paid-in capital":"1,180.76","Retained earnings (accumulated deficit)":"10,407.74","Other equity, total":"(3.55)","Total equity":"12,563.84","Total liabilities & shareholders' equity":"20,103.53","Total common shares outstanding":"978.90","Tangible book value per share, common eq":"7.27"},"Cash flow":{"Cash receipts":"14,443.31","Cash payments":"(3,009.90)","Cash taxes paid":"(1,859.85)","Changes in working capital":"(7,601.73)","Cash from operating activities":"1,971.83","Capital expenditures":"(535.97)","Other investing cash flow items, total":"24.59","Cash from investing activities":"(511.37)","Financing cash flow items":"(2.16)","Total cash dividends paid":"(384.78)","Issuance (retirement) of debt, net":"(505.23)","Cash from financing activities":"(892.16)","Foreign exchange effects":"0.96","Net change in cash":"569.26"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"30.30","52 Week High":"39.45","52 Week Low":"26.69","Pricing date":"","10 Day Average Trading Volume":"8.47","Market Capitalization":"29,660.67","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"131.87","Beta":"0.77","1 Day Price Change":"0.40","13 Week Price Return (Daily)":"4.30","26 Week Price Return (Daily)":"-15.27","5 Day Price Return (Daily)":"4.02","52 Week Price Return (Daily)":"3.66","Year To Date Price Return (Daily)":"-4.36","Month to Date Price Return (Daily)":"3.80","Price Relative to S&P500 (4 Week)":"-6.93","Price Relative to S&P500 (13 Week)":"-18.00","Price Relative to S&P500 (26 Week)":"-33.63","Price Relative to S&P500 (52 Week)":"-29.55","Price Relative to S&P500 (YTD)":"-26.85"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"2.16","EPS excl. Extra Items (TTM)":"1.51","EPS Normalized (Annual)":"1.65","Revenue per Share (Annual)":"15.02","Revenue per Share (TTM)":"14.67","Book Value (Per Share Annual)":"12.83","Book Value (Per Share Quarterly)":"13.38","Tangible Book Value (Per Share Annual)":"7.27","Tangible Book Value (Per Share Quarterly)":"6.48","Cash Per Share (Per Share Annual)":"3.11","Cash Per Share (Per Share Quarterly)":"3.49","Cash Flow (Per Share Annual)":"2.53","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.43","Dividends (Per Share TTM)":"0.43","EBITD (Per Share TTM)":"1.99","EPS Basic excl. Extra Items (Annual)":"2.16","EPS Basic excl. Extra Items (TTM)":"1.51","EPS incl. Extra Items (Annual)":"2.16","EPS incl. Extra Items (TTM)":"1.51","Free Cash Flow (Per Share TTM)":"1.41","Dividend (Per Share 5Y)":"0.32"},"Valuation":{"P/E excl. Extra Items (Annual)":"14.04","P/E excl. Extra Items (TTM)":"20.05","P/E Normalized (Annual)":"18.33","Price to sales (Annual)":"2.02","Price to sales (TTM)":"2.07","Price to Tangible Book (Annual)":"4.17","Price to Tangible Book (Quarterly)":"4.67","Price to Free Cash Flow (Per Share Annual)":"28.22","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"21.45","Price to Book (Annual)":"2.36","Price to Book (Quarterly)":"2.26","P/E Basic excl. Extra Items (TTM)":"18.43","P/E excl. Extra Items High (TTM)":"29.10","P/E excl. Extra Items Low (TTM)":"12.34","P/E incl. Extra Items (TTM)":"20.05","Net Debt (Interim)":"-3,032.31","Net Debt (Annual)":"-2,693.29","Dividend Yield (5Y)":"1.17","Dividend Yield":"1.42","Current Dividend Yield (TTM)":"1.42"},"Financial Strength":{"Free Cash Flow (Annual)":"1,051.08","Current Ratio (Annual)":"1.54","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"19.93","Quick Ratio (Annual)":"1.32","Total Debt/Total Equity (Annual)":"2.78","Current EV/Free Cash Flow (Annual)":"17.57","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.51","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"1.26","Total Debt/Total Equity (Quarterly)":"2.90","Free Cash Flow (TTM)":"1,382.50","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"28.46"},"Margins":{"Gross Margin (Annual)":"67.15","Gross Margin (TTM)":"65.40","Net Profit Margin % (Annual)":"14.55","Net Profit Margin (TTM)":"10.51","Operating Margin (Annual)":"17.20","Operating Margin (TTM)":"12.73","Pretax Margin (TTM)":"12.98","Pretax Margin (Annual)":"17.47","Operating Margin (5Y)":"15.07","Pretax Margin (5Y)":"15.66","Free Operating Cash Flow/Revenue (5Y)":"7.64","Free Operating Cash Flow/Revenue (TTM)":"9.63","Gross Margin (5Y)":"65.56","Net Profit Margin (5Y)":"13.22"},"Management Effectiveness":{"Return on Assets (Annual)":"11.22","Return on Equity (TTM)":"7.93","Return on Average Equity (Annual)":"18.06","Return on Average equity (TTM)":"11.79","Return on Investment (Annual)":"17.49","Return on Investment (TTM)":"11.51","Return on Average Assets (5Y)":"9.87","Return on Average Equity (5Y)":"15.68","Return on Investment (5Y)":"14.71","Asset Turnover (Annual)":"0.77","Asset Turnover (TTM)":"0.75","Inventory Turnover (Annual)":"3.26","Inventory Turnover (TTM)":"3.39","Net Income/Employee (Annual)":"142,805.50","Net Income/Employee (TTM)":"101,131.50","Receivables Turnover (Annual)":"5.80","Receivables Turnover (TTM)":"5.93","Revenue/Employee (Annual)":"981,502.00","Revenue/Employee (TTM)":"962,635.30"},"Growth":{"Revenue Growth (Quarterly YoY)":"-9.91","Revenue Growth Rate (5Y)":"15.10","EPS Growth (Quarterly YoY)":"-54.29","EPS Growth (TTM YoY)":"-32.03","EPS Growth Rate (5Y)":"15.32","Dividend Growth Rate (3Y)":"39.03","Revenue Growth (TTM YoY)":"6.11","Revenue Growth (Per Share 5Y)":"15.10","Revenue Growth Rate (3Y)":"17.85","EPS Growth Rate (3Y)":"20.82","Book Value Growth Rate (Per Share 5Y)":"13.20","Tangible Book Value Total Equity CAGR (5Y)":"9.88","Capital Spending growth rate 5 year":"9.45","EBITDA CAGR (5Y)":"9.26","EBITDA Interim CAGR (5Y)":"10.38","Free Operating Cash Flow CAGR (5Y)":"13.70","Total Debt CAGR (5Y)":"-14.57","Net Profit Margin Growth Rate (5Y)":"-0.25"},"Income Statement":{"Revenue (Annual)":"14,701.92","Revenue (TTM)":"14,356.74","EBITD (Annual)":"2,255.36","EBITD (TTM)":"1,945.20","Earnings Before Taxes (Annual)":"2,568.63","Earnings Before Taxes (TTM)":"1,863.56","Net Income to Common (Annual)":"2,112.50","Net Income to Common (TTM)":"1,478.96","Earnings Before Taxes Normalized (Annual)":"1,975.36","Net Income Available to Common Normalized (Annual)":"1,618.43","Diluted Normalized EPS excl. Extra Items (TTM)":"1.69"}}}